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Increasing evidence demonstrates that IL-6 has a protective role during liver injury. IL-6 activates intracellular 
pathways via the gp130 receptor. In order to identify IL-6–gp130 pathways involved in mediating liver protec-
tion, we analyzed hepatocyte-specific gp130 knockout mice in a concanavalin A–induced (Con A–induced) 
model of immune-mediated hepatitis. We demonstrated that IL-6–gp130–dependent pathways in hepatocytes 
alone are sufficient for triggering protection in Con A–induced hepatitis. gp130-STAT3 signaling in hepatocytes 
mediates the IL-6–triggered protective effect. This was demonstrated by analysis of IL-6–induced protection 
in mice selectively deficient for gp130-dependent STAT1/3 or gp130-SHP2-RAS signaling in hepatocytes. To 
identify IL-6–gp130–STAT1/3 dependently expressed liver-protective factors, we performed gene array analy-
sis of hepatic gene expression in hepatocyte-specific gp130–/– mice as well as in gp130-STAT1/3– and gp130-
SHP2-RAS-MAPK–deficient mice. The mouse IL-8 ortholog KC (also known as Gro-α) and serum amyloid 
A2 (SAA2) was identified as differentially IL-6–gp130–STAT3–regulated genes. Hepatic expression of KC and 
SAA2 mediate the liver-protective potential of IL-6, since treatment with recombinant KC or serum SAA2 
effectively reduced liver injury during Con A–induced hepatitis. In summary, this study defines IL-6–gp130–
STAT3–dependent gene expression in hepatocytes that mediates IL-6–triggered protection in immune-medi-
ated Con A–induced hepatitis. Additionally, we identified the IL-6–gp130–STAT3–dependent proteins KC and 
SAA2 as new candidates for therapeutic targets in liver diseases.
Introduction
Various etiologies result in acute and chronic liver diseases. Par-
ticularly in autoimmune and viral hepatitis, immune-mediated 
mechanisms play a central role and thus determine disease pro-
gression. In recent years, major progress has been made in treat-
ing these patients. However, there are still a high percentage of 
individuals for whom all treatment options fail and liver trans-
plantation is required. Therefore, alternative treatment options are 
needed; therapeutic approaches that either inhibit immune-medi-
ated mechanisms or directly inhibit liver cell damage are promis-
ing and might enter into the clinic.
IL-6 is a pleiotropic cytokine with beneficial effects for the liver. 
This cytokine promotes liver regeneration and protects against a 
multitude of liver-damaging influences such as alcohol and CCl4 
intoxication (1–4). IL-6 prevents apoptosis and exhibits positive 
effects in both ischemia/reperfusion models and fatty liver trans-
plantation (5–7). Additionally, IL-6 is known to efficiently reduce 
the increase of serum transaminases (ASTs) in the concanavalin A 
(Con A) mouse model of T cell–mediated hepatitis (1).
Con A–induced liver damage is a well-defined experimental ani-
mal model of acute hepatitis. It mimics human viral and autoim-
mune hepatitis in many aspects (8–10). Con A–induced hepatitis is 
accompanied by an increase in the serum concentration of several 
cytokines, including TNF-α, IFN-γ, IL-6, and IL-1. During the early 
stages, TNF-α and IFN-γ directly mediate liver cell damage (11). 
The cell types involved in the initiation and propagation of Con 
A–induced hepatitis (neutrophils: CD4+ T cells, CD8+ T cells, NK 
T cells [NKT cells], and Kupfer cells) have been directly implicated 
in a number of human liver diseases, including autoimmune, viral, 
alcoholic, and ischemia/reperfusion injury (12–18).
The IL-6–triggered molecular mechanisms leading to liver protec-
tion are not completely understood. For signal transduction, IL-6 
binds the membrane-bound IL-6 receptor α (gp80). The IL-6–gp80 
dimer interacts with gp130, the signal transducing unit in this 
complex. Gp130 is the common signal transducer used by the IL-6 
family of cytokines, which includes IL-6, leukemia inhibitory factor 
(LIF), IL-11, cardiotrophin-1 (CT-1), oncostatin-M (OSM), and the 
ciliary neurotrophic factor (19). The initiated intracellular signal-
ing is strictly dependent on the function of gp130 (19). Formation 
of gp130-containing complexes results in activation of intracellular 
JAKs, which phosphorylate tyrosine residues in the cytoplasmic 
domain of gp130. The phosphorylation of gp130 leads to dimer-
ization of gp130 and activation of STAT1 and STAT3 as well as 
the SHP2-RAS-MAPK pathway (where SHP2 is Src homology 2 
[SH2] domain–containing protein tyrosine phosphatase) (20–22). 
The use of distinct downstream signaling pathways from different 
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phosphorylation sites of the gp130 intracellular domain enables 
ligand- and tissue-specific activation of specific target genes. For 
these reasons, IL-6 signaling allows a complex plasticity (23, 24).
The aim of the present study is to identify the IL-6–gp130-depen-
dent pathways and the cell type that confer protection during Con A– 
induced liver injury. The identification of the responsible tar-
get cell and the essential intracellular signal cascade will help to 
clarify liver protective mechanisms and to identify IL-6–depen-
dent molecular mediators that contribute to beneficial effects in 
immune-mediated liver diseases.
Results
IL-6–gp130–dependent signaling in hepatocytes confers protection in the 
Con A model. The cytokine IL-6 triggers liver protection in the Con 
A model of T cell–mediated hepatitis. IL-6 controls gene tran-
scription in various cell types that might be involved in protec-
tive mechanisms, e.g., hepatocytes and immune-activated cells. 
Hepatocytes are the predominant hepatic cells; therefore, we evalu-
ated whether hepatocytes mediate IL-6–dependent protection in 
the Con A model. We generated mice with a hepatocyte-specific 
deletion of the IL-6 signal–transducing gp130 receptor (25) and 
analyzed the effect of IL-6 treatment in this experimental hepatitis 
model. Hepatocyte-specific gp130-deficient mice were generated 
by crossbreeding alfpCre and gp130loxP mice, in which LoxP sites 
flank exon 16, encoding the transmembrane domain of gp130 (26). 
Expression of Cre recombinase is controlled by a hepatocyte-spe-
cific albumin promoter, and results in a more than 90% deletion 
of exon 16 in adult liver (25). Since nonparenchymal cells show no 
gp130 deletion, the overall extent of hepatic gp130 inactivation is 
likely to reflect complete gp130 deletion in hepatocytes.
Gp130 wild-type (gp130LoxP/LoxP) animals were treated with IL-6 or 
vehicle before Con A injection. In order to monitor liver cell damage, 
AST levels were determined before and at various time points after 
treatment. IL-6 pretreatment completely blocked liver cell damage. 
No increase in transaminases was evident (Figure 1A). In alfpCre 
gp130LoxP/LoxP mice, IL-6 failed to have a protective effect, which 
indicates that IL-6–dependent liver protection is dependent on 
gp130-mediated signaling in hepatocytes (Figure 1B). 
Additionally, all alfpCre gp130LoxP/LoxP mice died within 
the first 20 hours after Con A injection. In contrast, all 
NaCL- and IL-6–treated wild-type animals survived 
during this phase, indicating a higher sensitivity of alf-
pCre gp130LoxP/LoxP mice toward Con A.
Lack of gp130 expression in hepatocytes has no impact on 
liver-damaging cytokine secretion after Con A injection. Dur-
ing Con A–induced hepatitis, immune cells are activat-
ed, and as a consequence, cytokines that promote liver 
cell damage are released. TNF-α and IFN-γ are essen-
tial in triggering Con A–induced liver injury. Addi-
tionally, IFN-γ and TNF-α are markers of immune-cell 
activation in this model. They are expressed by activat-
ed macrophages or CD4+ and CD8+ cells (1, 3, 27, 28). 
Therefore, we were interested in studying whether lack 
of gp130 expression in hepatocytes and IL-6 pretreat-
ment have an impact on cytokine secretion.
IL-6 treatment of gp130LoxP/LoxP mice resulted in a 
slight reduction of TNF-α levels compared with those 
in animals treated with the carrier solution (Figure 2A). 
The same observation was evident in alfpCre 
gp130LoxP/LoxP animals. Slightly reduced TNF-α levels 
were observed in the IL-6–treated group (Figure 2B). IL-6 pretreat-
ment had no impact on IFN-γ secretion in wild-type and alfpCre 
gp130LoxP/LoxP animals (Figure 2, C and D).
The endogenous IL-6 levels during Con A–induced hepatitis are signifi-
cantly elevated in alfpCre gp130LoxP/LoxP mice. In wild-type mice, a sig-
nificant increase in IL-6 serum concentration was observed during 
the first hours of Con A–induced hepatitis (Figure 2E). The IL-6 
serum levels returned to basal levels 24 hours after Con A injec-
tion. IL-6 pretreatment reduced IL-6 serum levels at later time 
points (Figure 2E). A different IL-6 kinetic was evident in alfpCre 
gp130LoxP/LoxP animals. In both groups, a marked increase in IL-6 
serum levels was obvious during the first hours after Con A injec-
tion. Additionally, IL-6 remained elevated during the first 24 hours 
in both groups (Figure 2F).
The IL-6–gp130–dependent activation of STAT3 in wild-type mice is sup-
pressed in alfpCre gp130LoxP/LoxP animals. To distinguish between the 
intracellular events that occur in wild-type and alfpCre gp130LoxP/LoxP 
animals during Con A–induced liver cell damage, we analyzed 
hepatic STAT1 and STAT3 activation during disease progression. 
Earlier studies indicated that STAT1 plays a harmful role during 
activation of CD4+ and NKT cells (29). Therefore, we studied nucle-
ar translocation of phosphorylated STAT1 and STAT3 in the liver.
IL-6 pretreatment had no impact on hepatic STAT1 activa-
tion in wild-type or in alfpCre gp130LoxP/LoxP mice (Figure 3A; 
0 hours, Con A) (25). Con A injection resulted in STAT1 activa-
tion in wild-type and alfpCre gp130LoxP/LoxP mice, but no remark-
able differences were found between the 2 groups (Figure 3A). IL-6 
pretreatment resulted in a slight increase of STAT1 phosphoryla-
tion in wild-type mice 2 hours and 4 hours after Con A injection 
(Figure 3A). In alfpCre gp130LoxP/LoxP animals, IL-6 injection 
resulted in a stronger and earlier STAT1 phosphorylation than in 
wild-type mice. Eight hours after Con A injection, STAT1 activa-
tion returned to basal levels (Figure 3A).
Activation of STAT3 during Con A–induced hepatitis can be 
divided into 3 phases (Figure 3B). The prephase, before Con A injec-
tion (0 hours), the immediate phase, 2 hours after injection, and 2 
later phases, 4 and 8 hours after initiation of the disease.
Figure 1
gp130 in hepatocytes is essential for IL-6–dependent protection in Con A–induced 
hepatitis. Con A hepatitis was induced by intravenous injection of 32.5 mg/kg Con A in 
wild-type (gp130LoxP/LoxP) and hepatocyte-specific gp130-null (alfpCre gp130LoxP/LoxP) 
mice. Mice were pretreated for 3 hours with NaCl (solid line) or IL-6 (200 μg/kg) (dot-
ted line) before i.v. injection of Con A. Liver injury was quantified by detection of AST. 
(A) Time course of AST serum levels during Con A–induced hepatitis in wild-type 
mice pretreated with NaCl (solid line) or IL-6 (dotted line). #P < 0.01 and *P < 0.05 
vs. corresponding IL-6–pretreated wild-type control group at the same time point. 
(B) Time course of AST serum levels during Con A–induced hepatitis in alfpCre 
gp130LoxP/LoxP mice pretreated with NaCl (solid line) or IL-6 (dotted line).
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To differentiate between STAT3 activation in hepatocytes and 
other liver cells we performed coimmunfluorescence stainings of 
CD11b and P-STAT3. In the prephase, STAT3α phosphorylation 
was exclusively detectable in hepatocytes of IL-6–pretreated wild-
type animals, but not in IL-6–injected alfpCre gp130LoxP/LoxP ani-
mals (Figure 3B; 0 hours, Con A).
Two hours after Con A injection, IL-6 pretreatment resulted in 
stronger STAT3α activation in wild-type and alfpCre gp130LoxP/LoxP 
animals compared to that in the NaCl-treated groups (Figure 3B). 
During this phase, STAT3 was predominately expressed in acti-
vated monocytes, NK cells, and macrophages (Figure 3C; CD11b+ 
cells). IL-6 pretreatment enhanced the number of STAT3-positive 
cells (Figure 3C).
At the later phase, 4 hours after Con A injection, strong P-STAT3α 
and P-STAT3β signals were found exclusively in hepatocytes of 
NaCl-treated wild-type mice. This strong STAT3 activation was 
found in neither of the other groups (Figure 3, B and D). Increased 
STAT3 activation 4 hours after Con A injection depended on gp130 
expression in hepatocytes. IL-6 pretreatment reduced STAT3 activa-
tion in hepatocytes in wild-type animals (Figure 3D). In hepatocyte-
specific gp130–/– mice, only a weak STAT3 activation 
in nonparenchymal liver cells (CD11b+ cells) was 
detectable. This activation was independent of IL-6 
pretreatment (Figure 3D).
Generation and molecular characterization of hepatocyte-
specific gp130ΔSTAT/LoxP and gp130Y757F/LoxP mice. Since 
gp130 expression in hepatocytes is essential for IL-6– 
induced protection in Con A–induced hepatitis, we 
aimed to identify the intracellular signaling pathways 
that are responsible for mediating protection. For this 
purpose, we generated mice with hepatocyte-specific 
deletions of either gp130-STAT1/3 or gp130-SHP2-
RAS-MAPK signaling. The activation of the 2 distinct 
signaling cascades in response to ligand-mediated 
gp130 dimerization is mediated by phosphorylation 
of specific tyrosines (Y) in the cytoplasmatic domain 
of gp130. Y757 mediates the engagement of the cyto-
plasmic Src-homology tyrosine phosphatase (SHP2) 
and the activation of the RAS-ERK pathway (30). The 
4-membrane distal phosphotyrosines are binding 
sites for the SH2 domains of the latent transcription 
factors STAT1 and STAT3 (31).
The alfpCre gp130ΔSTAT/ LoxP and alfpCre 
gp130Y757F/LoxP animals were obtained by crossing 
alfpCre gp130LoxP/LoxP with either gp130ΔSTAT/ΔSTAT or 
gp130Y757F/YY757F knockin mice (32). Gp130ΔSTAT/ΔSTAT 
mice express a truncated gp130 protein that lacks 
the part of the cytoplasmic domain required 
for STAT1 and STAT3 binding and activation. 
Gp130Y757F/Y757F animals express a gp130 protein 
with a phenylalanine substitution of the Y757 resi-
due which, in its phosphorylated form, is essential 
for SHP2 recruitment and subsequent activation 
of the RAS-MAPK cascade. In the resulting alfp-
Cre gp130ΔSTAT/LoxP and alfpCre gp130Y757F/LoxP ani-
mals, the LoxP-flanked gp130 is deleted selectively 
in hepatocytes as expression of Cre recombinase is 
controlled by a hepatocyte-specific promoter (25). 
This approach therefore enables the selective expres-
sion of mutant gp130 protein in hepatocytes. Each 
mouse was genotyped by PCR analysis for the genomic existence of 
Cre, gp130LoxP, and the respective mutant gp130 allele.
Functional characterization of the alfpCre gp130ΔSTAT/LoxP and alf-
pCre gp130Y757F/LoxP animals was performed by IL-6 stimulation in 
primary hepatocytes isolated from the 4 strains. IL-6–induced acti-
vation of gp130-dependent pathways was studied by the monitor-
ing of P-STAT1/3 and P-ERK2 expression. Treatment of wild-type 
primary hepatocytes resulted in phosphorylation of STAT3 and 
ERK2 (Figure 4B). Neither protein was phosphorylated (and hence 
activated) in hepatocytes derived from alfpCre gp130LoxP/LoxP mice 
(Figure 4C). However, in hepatocytes isolated from IL-6–stimulated 
alfpCre gp130Y757F/LoxP or alfpCre gp130ΔSTAT/LoxP mice, we observed 
selective activation of P-STAT3 or P-ERK2, respectively (Figure 4, 
D and E). P-STAT1 activation was neither induced in IL-6– 
stimulated primary hepatocytes isolated from wild-type, alfpCre 
gp130LoxP/LoxP, alfpCre gp130Y757F/LoxP, nor alfpCre gp130ΔSTAT/LoxP 
animals (data not shown).
Activation of the IL-6–gp130–STAT pathway in hepatocytes con-
fers protection during Con A–induced liver damage. We used alfpCre 
gp130Y757F/LoxP and alfpCre gp130ΔSTAT/LoxP animals to identify the 
Figure 2
Cytokine secretion during Con A–induced hepatitis. Cytokine levels in the serum 
after Con A injection in wild-type (gp130LoxP/LoxP) and alfpCre gp130LoxP/LoxP mice. 
Three hours before Con A administration, animals were treated with NaCl (solid line) 
or IL-6 (200 μg/kg) (dotted line) by i.p. injection. (A and B) TNF-α levels of wild-type 
and alfpCre gp130LoxP/LoxP mice. #P < 0.01 vs. corresponding IL-6–pretreated wild-
type control group at the same time point. (C and D) IFN-γ levels of wild-type and 
alfpCre gp130LoxP/LoxP mice. (E and F) IL-6 concentrations of wild-type and alfpCre 
gp130LoxP/LoxP mice. §P < 0.001 and #P < 0.01 vs. corresponding IL-6–pretreated wild-
type or alfpCre gp130LoxP/LoxP mice at the same time point.
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gp130-dependent pathways in hepatocytes essential for mediating 
IL-6–dependent protection during Con A–induced hepatitis. IL-6 
pretreatment of alfpCre gp130Y757F/LoxP mice resulted in complete 
prevention of liver cell damage (Figure 5A). In contrast, alfpCre 
gp130ΔSTAT/LoxP animals showed enhanced sensitivity toward Con A 
when compared to wild-type mice (Figure 5B). Independently of 
IL-6 pretreatment, all alfpCre gp130ΔSTAT/LoxP mice died within 8 
hours after Con A injection in contrast to a 100% survival rate for 
all analyzed alfpCre gp130Y757F/LoxP animals.
To analyze possible modifications of immune-cell activation 
in these animals, serum TNF-α, IFN-γ, and IL-6 levels were deter-
mined before and after Con A injection (Figure 5, C and D). IL-6 
pretreatment in alfpCre gp130Y757F/LoxP or alfpCre gp130ΔSTAT/LoxP 
animals had no significant impact on TNF-α serum levels 
(Figure 5D). In both mouse strains, IL-6 treatment resulted in 
slightly elevated IFN-γ serum levels (Figure 5, B and C). Addition-
ally, IL-6 serum levels did not differ between the vehicle-treated 
alfpCre gp130Y757F/LoxP and alfpCre gp130ΔSTAT/LoxP animals. In 
both mouse strains, we detected maximal IL-6 concentrations 8 
hours after Con A injection (Figure 5D). In contrast, pretreatment 
with recombinant IL-6 resulted in a reduction of endogenous IL-6 
serum concentrations during Con A–induced hepatitis in alfpCre 
gp130Y757F/LoxP animals (Figure 5C). No reduction of IL-6 serum 
levels was observed in alfpCre gp130ΔSTAT/LoxP mice (Figure 5D).
Gene expression profiles of IL-6–gp130 pathways in hepatocytes. The 
analysis of hepatocyte-specific gp130 mutations during Con A–
induced hepatitis demonstrated that IL-6–gp130–STAT3–depen-
dent signals appear to confer protection. To identify potential 
target genes involved in mediating protection, hepatic gene expres-
sion profiles were determined in IL-6–treated wild-type, alfpCre 
gp130LoxP/LoxP, alfpCre gp130Y757F/LoxP, and alfpCre gp130ΔSTAT/LoxP 
mice. Figure 6 depicts a selection of genes that are significantly 
regulated by gp130-dependent pathways in hepatocytes in vivo. 
These can be divided into 2 groups: genes involved in controlling 
gp130-dependent signaling in the cell, e.g., stat-1, stat-3, socs-1 (sup-
pressor of cytokine signaling-1) and socs-3; and genes regulating 
immune-mediated mechanisms, e.g., serum amyloid A2 (saa2) and 
keratinocyte growth factor (kc). As the gp130-STAT3–dependent 
pathway confers protection in the Con A model, we hypothesized 
that indirect immune-mediated mechanisms were essential for 
protection against liver damage in the Con A model.
Treatment with SAA2 and KC protects against Con A–induced liver 
damage. We analyzed in more detail the regulation of saa and kc 
and their potential roles during Con A–induced liver failure. Both 
Figure 3
Changes in liver nuclear phosphorylation of STAT1 and STAT3 during Con A–induced hepatitis. (A) Phosphorylation of STAT1 in wild-type and 
alfpCre gp130LoxP/LoxP mice. Western blot analysis of STAT1 and STAT3 activation, as detected by phosphorylation of STAT1 and STAT3, in liver 
nuclear protein extracts of wild-type and alfpCre gp130LoxP/LoxP mice. Animals were pretreated 3 hours before Con A administration with NaCl or IL-6 
(200 μg/kg) by i.p. injection as indicated. Representative results of 3 independent experiments are shown. (B) Phosphorylation of STAT3 in wild-type 
and alfpCre gp130LoxP/LoxP mice. (C) Double immunofluorescence of liver sections for P-STAT3 and CD11b expression. CD11b detects activated 
macrophages, NK cells, and monocytes. Mice were killed 2 hours after Con A injection. DAPI counterstaining was used to detect nuclei. (D) Double 
immunofluorescence of liver sections for P-STAT3 and CD11b expression. CD11b detects activated macrophages, NK cells, and monocytes. Mice 
were killed 4 hours after Con A injection. Representative areas are shown. Slides of 3 animals per group were analyzed. Magnification, ×400.
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genes are selectively induced via IL-6–gp130–STAT3. The analysis 
of SAA serum expression showed that pronounced transcriptional 
induction of the saa gene strictly depended on IL-6–gp130–STAT3 
signaling in hepatocytes. In order to confirm the array analysis, 
we also investigated hepatic mRNA expression (data not shown) 
and serum levels of SAA and found that both were elevated only in 
wild-type and alfpCre gp130Y757F/LoxP mice (Figure 7A).
SAA is known to interact with metalloproteinases and to influ-
ence the activity of immune cells (33). Therefore, we studied the 
impact of SAA on Con A–induced hepatitis by pretreating wild-
type animals with recombinant SAA 1 hour before Con A injection. 
SAA injection resulted in a significant reduction in the increase 
of AST levels compared with those in vehicle-treated control ani-
mals, indicating that SAA may have a protective effect for Con A– 
induced liver damage (Figure 7B).
KC controls chemotaxis and activation of polymorph nuclear 
cells (PMNs) in areas of inflammation. Serum KC expression was 
also strictly dependent on an intact IL-6–gp130–STAT3–signaling 
axis in hepatocytes (Figures 6 and 7C). No hepatic KC regulation 
was found in alfpCre gp130ΔSTAT3/LoxP and alfpCre gp130LoxP/LoxP 
animals. Earlier results showed that the preexistence of high KC 
concentration in the serum leads to decreased PMN infiltration 
during inflammation (34). This effect is caused by reduced sensi-
tivity of downstream pathways of the corresponding chemokine 
receptor (34). We thus analyzed the influence of IL-6 pretreat-
ment on PMN infiltration during Con A–induced hepatitis. IL-6 
treatment resulted in a significant reduction of PMN infiltration 
4 hours after Con A injection (Figure 7D). This time coincided 
with the maximum of PMN infiltration. In order to further inves-
tigate the relevance of this observation, recombinant KC was 
injected before Con A administration. KC had a protective effect 
on Con A–induced T cell–mediated liver failure. The increase in 
transaminases was significantly blocked in the animals treated 
with KC (Figure 7E). Additionally, KC treatment leads to 100% 
survival during Con A–induced hepatitis compared with 70% in 
NaCL-treated animals.
Discussion
Con A injection into mice results in T cell activation in the liver 
as well as hepatocyte damage. The mechanisms during Con A–
induced disease progression resemble human liver diseases, e.g., 
autoimmune disease and viral hepatitis (12–18). Therefore, the 
Figure 4
Generation and functional characterization of hepatocyte-specific gp130ΔSTAT/LoxP and gp130Y757F/LoxP mice. (A) alfpCre gp130LoxP/LoxP mice were 
generated by breeding alfpCre mice with animals expressing LoxP-flanked gp130 alleles (25). Hepatocyte-specific gp130ΔSTAT/LoxP animals (alfpCre 
gp130ΔSTAT/LoxP) were generated by crossing alfpCre gp130LoxP/LoxP with gp130ΔSTAT/ΔSTAT mice, which express a truncated gp130 knockin allele encod-
ing a truncated gp130 protein that lacks the domains mediating STAT1 and STAT3 activation (26). Hepatocyte-specific gp130Y757F/LoxP animals (alfp-
Cre gp130Y757F/LoxP) were bred by crossing alfpCre gp130LoxP/LoxP with gp130Y757F/Y757F mice, which express a gp130 allele encoding a phenylalanine 
substitution of the Y757 residue (32), thereby rendering gp130 incapable of recruiting SHP2 and activating the RAS-MAPK pathway. Animals were 
genotyped by PCR analysis for alfpCre, gp130LoxP, and gp130Y757F alleles. (B and E) The functional characterization of hepatocyte-specific gp130 
mutant mice. Gp130 downstream-signaling pathways were analyzed by monitoring of phosphorylated STAT3 and phosphorylated ERK2 (p42) 
expression in whole cell extracts of primary hepatocytes isolated from wild-type (B), alfpCre gp130LoxP/LoxP (C), alfpCre gp130Y757F/LoxP (D), or alfp 
Cre gp130ΔSTAT/LoxP mice (E). Activation of phosphorylated STAT1 was not detected in any of the 4 mouse strains.
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model is attractive for exploring mechanisms that might ultimate-
ly result in new therapeutic options.
We analyzed mice with mutations in the gp130 receptor in 
hepatocytes that selectively impair the signaling capacity of this 
receptor. Functional inactivation of this molecule in hepatocytes 
resulted in lack of signal activation after stimulation with ligands 
of the IL-6 cytokine family, e.g., IL-6 or OSM. Further experi-
ments in hepatocyte-specific knockout animals showed that lack 
of gp130 expression in hepatocytes renders these animals more 
susceptible to injury during various pathophysiological condi-
tions of the liver (25). Therefore, the aim of the present study was 
to identify molecular mechanisms that are involved in mediating 
IL-6–gp130–dependent protection in hepatocytes.
Earlier studies demonstrated that IL-6 attenuated liver injury in 
Con A–induced hepatitis (1). Additionally, recent reports demon-
strated that other IL-6 family members, e.g., IL-11 and CT-1, also 
confer protection in this model (35, 36). As all IL-6 family members 
use the gp130 receptor for signal transduction, our aim was to deter-
mine the cell type that confers protection in this model. Interesting-
ly, when gp130 was selectively deleted in hepatocytes, IL-6 no longer 
conferred a protective effect (Figure 1). Moreover, in hepatocyte-spe-
cific gp130 knockout mice, Con A–induced liver injury was more 
pronounced and resulted in death of the animals within 24 hours, 
indicating that gp130-dependent pathways in liver cells are also pro-
tective in the later phase of Con A–induced liver injury.
In a recent study, Sun et al. also suggested that IL-6 might atten-
uate liver injury in Con A–induced hepatitis (37) by suppressing 
the activity of NKT cells. NKT cell activation is an important event 
in the initial phase of Con A–induced hepatitis (38). However, the 
IL-6 doses Sun et al. used were 10-fold higher than in the IL-6–
treatment schedule used in this study. Thus, the effect of IL-6 on 
NKT cell activation might be added to the more prominent effect 
triggered by IL-6 in hepatocytes.
Intracellular signaling mediated by gp130 is dependent on phos-
phorylation of tyrosine residues in the intracellular part of the recep-
tor. To dissect the contribution of the 2 major pathways engaged by 
Figure 5
gp130-STAT3 signaling in hepatocytes is responsible for IL-6–induced liver protection. Con A–induced hepatitis was induced by intravenous 
injection of 32.5 mg/kg Con A in hepatocyte-specific gp130ΔSTAT (alfpCre gp130ΔSTAT/LoxP) and hepatocyte-specific gp130Y757F/LoxP mice (alfpCre 
gp130Y757F/LoxP). Mice were pretreated 3 hours before Con A injection with NaCl (solid line) or IL-6 (200 ng/g) (dotted line) by i.p. injection. (A and B) 
Liver damage was quantified by detection of ASTs. (A) AST levels of alfpCre gp130Y757F/LoxPmice in the time course of Con A–induced hepatitis, pre-
treated with NaCl (solid line) or IL-6 (dotted line). #P < 0.01 and *P < 0.05 vs. corresponding IL-6–pretreated control group at the same time point. (B) 
AST levels of alfpCre gp130ΔSTAT/LoxP in the time course of Con A–induced hepatitis, pretreated with NaCl (solid line) or IL-6 (dotted line). (C and D) 
TNF-α, IFN-γ, and IL-6 secretion in the serum during Con A–induced hepatitis in alfpCre gp130Y757F/LoxP (C) and alfpCre gp130ΔSTAT/LoxP mice (D) 
was determined by ELISA. §P < 0.001 vs. corresponding IL-6–pretreated alfpCre gp130Y757F/LoxP mice at the same time point.
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gp130 activation, we combined gp130 knockin mutant animals with 
tissue-specific gp130 knockout animals in order to genetically restrict 
the capacity of gp130 to selectively activate only 1 of these 2 pathways 
in hepatocytes in vivo. Since this strategy relies on monoallelic expres-
sion of gp130, it is important to ensure that this manipulation does 
not confer the rate-limiting step for IL-6 signaling in hepatocytes. We 
have previously shown that the rate-limiting step during IL-6–depen-
dent signal transduction in this cell type is in fact expression of gp80 
on the cell surface (39, 40), and monoallelic ablation of gp130 by the 
LoxP/Cre technology did not change the strength of STAT3 activa-
tion after IL-6 stimulation (25). Experiments in primary hepatocytes 
isolated from these animal strains demonstrated that our concept is 
valid. Therefore, we addressed the question of which of the 2 gp130-
mediated intracellular pathways is essential to trigger IL-6–depen-
dent liver protection during Con A–induced hepatitis.
IL-6 stimulation of alfpCre gp130ΔSTAT/LoxP and alfpCre 
gp130Y757F/LoxP animals revealed that phosphorylation of the 4 
membrane distal tyrosine residues in gp130 that mediate activa-
tion of STAT3 are required to attenuate Con A–induced liver inju-
ry while the gp130-SHP2-RAS-MAPK pathway appears to be com-
pletely dispensable in mediating this effect. Interestingly, in our 
present and former experiments, IL-6 and OSM stimulation did 
not trigger STAT1 activation in the liver (25). Therefore, our find-
ings indicate that the protective effects are mediated by STAT3.
In further experiments, we analyzed whether IL-6 pretreatment 
induces changes in gp130-dependent signaling in hepatocytes. IL-6 
stimulation may have effects on cytokine secretion during Con A–
induced hepatitis. In particular, TNF-α and IFN-γ have been shown 
to play an essential role (41, 42). TNF-α is produced primarily by 
Kupffer cells in Con A–induced hepatitis (16). In wild-type mice, 
TNF-α levels were reduced after IL-6 stimulation. But in alfpCre 
gp130Y757F/LoxP mice, which retained sensitivity to IL-6–dependent 
liver protection, no changes in TNF-α levels were detected. These 
results indicate that a change in TNF-α serum levels is not essen-
tial for the protective effect mediated by IL-6.
IFN-γ is a marker of activated CD4+ cells and is strongly elevated 
after Con A injection (27, 42). IFN-γ levels in alfpCre gp130Y757F/LoxP 
and wild-type mice were not affected by pretreatment with IL-6, 
despite our observation that both strains showed protection from 
Con A–induced liver damage (Figure 2, C and D; Figure 5, C and D). 
Thus, serum levels of TNF-α and IFN-γ showed no correlation 
with the capacity of IL-6 to provide protection from liver damage, 
indicating that alterations in concentrations of these cytokines are 
unlikely to explain protection.
We next concentrated on mechanisms related to IL-6–dependent 
signaling in hepatocytes. IL-6 serum concentrations correlated 
with survival rates. High IL-6 serum concentrations after Con A 
injection were detectable in animals with a disruption of the IL-6– 
gp130–STAT3 pathway and correlated with increased morbidity. 
In contrast, IL-6–induced activation of STAT3 in hepatocytes prior 
to or 4 hours after Con A challenge was associated with survival of 
the animals. Lack of STAT3 activation in hepatocytes at these time 
points, as observed in alfpCre gp130LoxP/LoxP (Figure 1B) and alfpCre 
gp130ΔSTAT/LoxP (Figure 5B) animals, correlated with poor prognosis.
STAT3 activation 2 hours after Con A injection occurred predom-
inantly in activated immune cells, such as NK cells and infiltrating 
monocytes (CD11b+ cells) (Figure 3C, NaCl-treated groups). The 
pathways leading to STAT3 activation in these cells are currently 
unclear. gp130-dependent or gp130-independent factors, e.g., IFN-γ, 
could be relevant in explaining this observation (29).
IL-6 pretreatment increased the amount of phosphorylated 
STAT3 in nonparenchymal cells 2 hours after Con A injection by 
increasing numbers of P-STAT3–positive cells (Figure 3C). The 
increased number of STAT3-positive cells likely reflects IL-6– 
induced sensitization of NK cells, monocytes, or Kupffer cells to 
STAT3-activating pathways.
Four hours after Con A injection, STAT3 activation occurred 
predominately in hepatocytes in a gp130-dependent manner 
(Figure 3, B and D). Strong STAT3 activation in this phase cor-
related with maximal IL-6 serum levels (Figure 2E). IL-6 pretreat-
ment inhibited the increase of STAT3 activation in hepatocytes 
of wild-type mice, probably by inducing negative feedback mecha-
nisms, e.g., induction of SOCS-3 in hepatocytes (Figure 6).
It has been shown that SOCS-3 negatively regulates IL-6 signal-
ing in vivo (43). In agreement with these findings, we demonstrated 
that activation of STAT3 is transitional. Hepatocytes of IL-6–pre-
treated wild-type mice showed STAT3 activation 3 hours after IL-6 
injection. Up to 4 hours after initiation of Con A–induced hepati-
tis, these cells were not able to activate STAT3, although high IL-6 
serum levels were detectable (Figures 3D and 2E).
In order to define potential IL-6–gp130–STAT3 target genes 
in hepatocytes that might be involved in conferring protection 
during Con A–induced liver failure, we performed gene expres-
sion profiling. Interestingly some acute phase genes were strictly 
Figure 6
IL-6–induced gene expression profile of wild-type, alfpCre gp130LoxP/LoxP, 
alfpCre gp130Y757F/LoxP, and alfpCre gp130ΔSTAT/LoxP mice. Affimetrix 
GeneChip analysis was used to detect gene expression of IL-6–stimu-
lated gp130LoxP/LoxP, alfpCre gp130LoxP/LoxP, alfpCre gp130ΔSTAT/LoxP, and 
alfpCre gp130Y757F/LoxP mice. Three animals per group were treated in 
parallel by i.p. injection of recombinant IL-6 (IL-6 rα) (200 μg/kg) or 
NaCl. Liver RNA was isolated, and gene expression was compared. 
Most of the examples shown are differentially regulated by gp130-STAT 
signaling. Glycine receptor (Glycine R) and cytochrome p450 (p450) 
represent examples that are regulated by gp130-ras-MAPK signaling. 
The change of gene expression level is marked by increasing color 
intensity. LBP, LPS binding protein.
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regulated via IL-6–gp130–STAT3. SAA2 showed the most prom-
inent regulation. SAA2 is a known target of MMP and MMP 
activity induced during T cell–mediated hepatitis. Earlier experi-
ments have shown that inhibition of MMPs attenuates liver fail-
ure (44). Indeed, treatment with recombinant SAA2 attenuated 
Con A–induced liver injury (Figure 7B). Therefore, one of the 
mechanisms through which SAA2 might be protective is sub-
strate competition of MMP activity.
Activation of PMNs during Con A–induced liver failure is an 
essential step for disease progression (12). IL-6–treated mice 
showed a significant reduction in PMN infiltration during Con A– 
induced hepatitis (Figure 7D). Results of the gene expression 
analysis are remarkable in this context, as the CXC chemokine KC 
was strongly upregulated in response to activation of the IL-6– 
gp130–STAT3 pathway. KC is an immediate early gene with low 
or no detectable expression in most tissues. A variety of factors, 
such as LPS or PDGF, induce tissue-specific expression of KC 
(45), which in turn promotes localized PMN migration. How-
ever, KC alone is not sufficient for the activation of infiltrated 
cells, and high systemic KC levels lead to impaired PMN activa-
tion via desensitization of the PMN CXC–receptor 2 (46). IL-6 
stimulation induces KC serum levels by approximately 100-fold, 
correlating with a pronounced upregulating of KC mRNA in the 
liver (Figure 6). But IL-6–dependent hepatic KC expression by 
itself induces no influx of PMNs in the liver (data not shown). 
Our present analysis shows that KC confers protection in Con A– 
induced T cell–mediated hepatitis. These results indicate that 
high systemic KC levels directly attenuate immune cell activa-
tion, most likely via modulating PMN function. Additionally, 
recent studies showed effects of KC expression on monocyte 
recruitment during development of experimental atherosclero-
sis (47). Also, modulation of liver monocyte activation might be 
a mechanism by which the chemokine prevents Con A–induced 
liver damage. KC-mediated mechanisms might be of general 
interest for the study of various liver-damaging conditions and 
will be the subject of further research.
In conclusion, our present analysis suggests that IL-6–gp130–
dependent gene activation in hepatocytes confers protection 
against T cell hepatitis induced by Con A. Functional dissection 
of gp130-dependent pathways in hepatocytes demonstrates that 
Figure 7
Acute-phase protein SAA2 and the chemokine KC are IL-6–gp130–STAT–induced, liver-protective proteins. (A) SAA2 serum levels after IL-6 
(200 μg/kg) injection. Each time point represents the serum of 3–5 animals. Filled squares represent wild-type mice, open squares show alfpCre 
gp130LoxP/LoxP mice, filled triangles mark alfpCre gp130Y757F/LoxP mice, and open triangles represent alfpCre gp130ΔSTAT/LoxP. (B) Pretreatment with 
recombinant SAA (0.8 mg/kg) leads to a significant reduction of AST levels in the time course of Con A–induced hepatitis in wild-type mice. Either 
SAA (dotted line) or NaCl (solid line) was injected intravenously 1 hour before induction of Con A–induced hepatitis. (C) Serum KC levels after 
IL-6 injection. Filled squares represent wild-type mice, open squares show alfpCre gp130LoxP/LoxPmice, filled triangles mark alfpCre gp130Y757F/LoxP 
mice, and open triangles represent alfpCre gp130ΔSTAT/LoxP. (D) IL-6 treatment results in a significant reduction of PMN infiltration during Con A– 
induced hepatitis. Four hours after Con A injection, the influx of PMNs was counted on H&E-stained paraffin sections by an experienced liver 
pathologist. The arrows mark liver infiltrating PMNs. hPF, high powered field. (E) KC (40 μg/kg) treatment leads to a significant reduction of AST 
levels during Con A–induced hepatitis. Eight mice per group were treated with either KC (dotted line) or NaCl (solid line) 1 hour before Con A 
injection. §P < 0.001 and *P < 0.05 vs. corresponding control groups at the same time point.
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IL-6–mediated STAT3 activation correlates with reduced liver 
damage and induces hepatic expression of liver-protective pro-
teins SAA2 and KC. Both proteins are potent inhibitors of Con A– 
induced hepatitis and might also be of interest in the treatment of 
immune-mediated liver diseases in humans.
Methods
Animals
Specified pathogen–free 8- to 10-week-old male BALB/c mice were obtained 
from the Animal Research Institute of the Medizinische Hochschule Han-
nover. H. Hedrich, state head of the animal facility at the Hannover Medi-
cal School, approved the care of animals and experiments. For each time 
point and group, 3–5 animals were treated in parallel.
Generation and genotyping of gp130-mutated animals
AlfpCre gp130LoxP/LoxP. Hepatocyte-specific gp130–/– mice were generated 
by breeding alfpCre mice with mice expressing LoxP-flanked gp130 
alleles. Genomic DNA was isolated and analyzed by PCR as described 
previously (25). Gp130LoxP/LoxP mice without Cre expression were used as 
control (wild-type) animals.
AlfpCre gp130ΔSTAT/LoxP. Hepatocyte-specific gp130ΔSTAT/LoxP animals 
were generated by breeding alfpCre gp130LoxP/LoxP with gp130ΔSTAT/ΔSTAT 
knockin mice. Gp130ΔSTAT/ΔSTAT expresses a truncated gp130 knockin 
allele that lacks the essential region for the activation of STAT1 and -3 
signaling (48). The genotype was detected by PCR analysis for alfpCre, 
gp130LoxP, and gp130ΔSTAT allele as described previously (32, 48).
AlfpCre gp130Y757F/LoxP. Hepatocyte-specific gp130Y757F/LoxP animals were 
generated by crossing alfpCre gp130LoxP/LoxP with gp130Y757F/Y757F knockin 
mice. The gp130Y757F/Y757F mice express a gp130 allele with a point muta-
tion at Y757. The Y757 is the essential tyrosine for the recruiting of SHP2 
and the activation of downstream signals of the RAS-MAPK cascade (32). 
The genotype was analyzed by PCR analysis for alfpCre, gp130LoxP, and 
gp130Y757F allele as described previously (25, 32).
IL-6, SAA, KC, and Con A treatment
Con A–induced hepatitis was induced by intravenous injection of 32.5 mg/kg 
Con A. IL-6 (200 μg/kg) was injected i.p. 3 hours before Con A injection. 
Recombinant SAA (0.8 mg/kg) and recombinant KC (40 µg/kg) were 
applied by i.v. injection 1 hour before Con A administration. Control 
animals were injected with an equal volume of carrier solution (NaCl). 
Livers of IL-6–treated animals used for array analysis (at 0 hours) were 
perfused. To ensure that infiltrated cells in livers of Con A–treated mice 
were not eliminated, we washed the organs intensively by shaking the 
organs for 15 minutes in cold PBS.
Preparation of liver nuclear extracts
Liver nuclear extracts were prepared as described previously (49).
Quantification of hepatic PMNs
Sections of the livers of 4 mice per group were analyzed. From each liver 
slide, PMNs in 6 representative high-power fields were counted on an H&E 
stain by an experienced liver pathologist. Student’s t test was performed to 
evaluate the significance of detected differences.
Detection of nuclear p-STAT3, p-STAT1, and p-ERK
Activated STAT and ERK were analyzed by detection of phosphorylated 
nuclear proteins. Five μg of liver nuclear proteins were separated on a 10% 
SDS-polyacrylamide gel and blotted onto nitrocellulose membrane. Phos-
pho-STAT3 and phospho-STAT1 expression were analyzed by Western 
blot, using an antibody directed against tyrosine phosphorylated STAT3 
or STAT1 (Cell Signaling Technology). Phospho-ERK1/2 expression was 
analyzed by use of an antibody directed against phosphorylated ERK1/2 
(Cell Signaling Technology). The antigen-antibody complexes were visual-
ized using the ECL detection system as recommended by the manufacturer 
(Amersham Biosciences). To verify equal loading of protein samples, a Coo-
massie-blue stained SDS Gel was quantified.
Detection of p-STAT3 and CD11b+ cells
Cryosections of frozen livers were performed and slides were fixed 
in a combination of methanol and acetone. We performed CD11b– 
P-STAT3 double immunofluorescence staining. CD11b reacts to acti-
vated macrophages and Con A–activated monocytes. It thus serves as 
a marker for differentiation between STAT3-positive hepatocytes and 
STAT3-positive Con A–activated immune cells. CD11b–P-STAT3 dou-
ble staining was performed by using rat anti-mouse CD11b antibody 
(BD Biosciences — Pharmingen) in combination with rabbit anti-mouse 
P-STAT3 (Cell Signaling Technology). As a second antibody, a mix of 
Alexa Fluor 488 donkey anti-rat and Alexa Fluor 594 donkey anti-rabbit 
was used (Molecular Probes).
Determination of IL-6, TNF-α, IFN, KC, and SAA concentrations 
and AST activity
Blood was withdrawn by retro-orbital puncture at the indicated time 
points. TNF-α, IL-6, IFN-γ, KC, and SAA serum concentrations were detect-
ed by ELISA (mouse TNF; BD Biosciences — Pharmingen), mouse IL-6 (BD 
Biosciences — Pharmingen), mouse SAA (BioSource International), mouse 
KC (R&D Systems) as described previously (3).
Determination of ASTs
AST activity was determined by an automated enzyme assay as described 
previously (3).
Recombinant proteins
Recombinant IL-6 was produced and provided by S. Rose-John. Recom-
binant SAA was purchased from Cell Sciences. Recombinant KC was pur-
chased from Strathmann Biotec AG.
Gene expression profile analysis
Affymetrix mouse genome GeneChip arrays were used to analyze gene expres-
sion of IL-6–stimulated gp130LoxP/LoxP (wild-type), alfpCre gp130LoxP/LoxP, 
alfpCre gp130ΔSTAT/LoxP, and alfpCre gp130Y757F/LoxP mice. Three animals per 
group were treated in parallel by i.p.-injected recombinant IL-6 (200 μg/kg) 
or NaCl. After 3 hours, animals were sacrificed. Liver RNA was isolated by 
guanidine isothiocyanate isolation. The RNA was used for the Affymetrix 
GeneChips, as described in the manufacturer’s protocol. RNA of 3 mice 
per group was pooled. For each mouse strain, we compared mice treated 
with NaCl for 3 hours with those treated with IL-6 for 3 hours. Addition-
ally, nuclear proteins were isolated from each liver, and the activation of 
STAT3 and ERK1/2 was analyzed by Western blot to verify the integrity of 
IL-6 signaling in each mouse.
Isolation and stimulation of primary hepatocytes
Primary mouse hepatocytes were isolated by collagenase perfusion (50). 
Mouse liver was perfused with HEPES buffer, then with collagenase solu-
tion, in a retrograde fashion. Isolated hepatocytes were washed with PBS. 
1 × 106 cells were plated on 6 cm dishes in DMEM containing 10% fetal calf 
serum and a combination of penicillin and streptomycin. The medium was 
changed after 4 hours. The cells were cultured under serum-free conditions 
overnight. The next day, cells were stimulated with 200 ng/ml recombinant 
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IL-6. Cells were harvested at the indicated time points, and whole cell pro-
teins, RNA, and nuclear proteins were isolated.
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